<h1 itemprop="aspect"> <strong>Qnexa Side Effects</strong></h1><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2012/05/qnexa-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Qnexa" title="Qnexa" pagespeed_url_hash="1501640694" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><ul><li>Increased anxiety</li><li>Sleep disturbances</li><li>Dry mouth</li><li>Tingling</li><li>Constipation</li><li>Altered taste</li><li>Depression</li><li>Infections in the sinus and respiratory tracts</li></ul><div>There are more serious adverse side effects with Qnexa which include suicidal thoughts, memory lapse and complications during pregnancy.  The latter happens to be the foremost and outlying contraindication of Qnexa.</div></div><div class="v" id="tab2" ><h2 itemprop="aspect"> <strong> Warnings & Recalls for Qnexa </strong></h2><p>Since not much is known about this drug as it is still in the clinical trial and investigative phase of approval, so far the number one precaution with this drug is that it is contraindicated in women who are pregnant or plan on being pregnant.  Upon pregnancy, a female patient is strongly advised to stop taking Qnexa immediately.</p><p>Patients with a known history of heart problems are dissuaded from taking Qnexa.  There is also the problem of suicidal thoughts that have occurred with people taking this drug.</p><p>In October of 2012, the FDA had initially rejected Qnexa due to adverse side effects which included depression, suicidal thoughts, memory lapses and complications during pregnancy.  However citing a 2012 FDA panel, there was a 20:2 vote on approving Qnexa for the treatment of obesity.</p></div><div class="v" id="tab3" ><h2 itemprop="aspect"> <strong> Qnexa Treatment and Use </strong></h2><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2012/05/qnexa-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Qnexa" title="Qnexa" pagespeed_url_hash="1501640694" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><p>Qnexa | Phentermine and topiramate drug combination is a medication that is in clinical and investigative trials awaiting approval for treating obesity, type 2 diabetes and Qnexa has also been shown to lower blood pressure and cholesterol.  Qnexa is being developed and marketed by a California pharmaceutical company called Vivus.  Phentermine is an appetite suppressant as well as a stimulant and belongs to the amphetamine and phenethylamine class.  The drug classification of topiramate is that of an anticonvulsant that has shown significant weight loss results.</p><p>&nbsp;</p><p>On February 22, 2012, a FDA panel voted 20:2 to approve Qnexa as an anti-obesity treatment and final approval is expected later on in 2012.</p></div><div class="v" id="tab4" ><h2 itemprop="aspect"> Other Names for Qnexa</h2> Phentermine and topiramate combination</div><div class="v" id="tab5" ><h2 itemprop="aspect"> <strong> Lawsuits & Legal Information for Qnexa </strong></h2>